Janssen wins injunction against Juno in patent fight over generic Invega

Intellectual Property 2025-12-05 11:39 pm By Christine Caulfield

Please login to bookmark

Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au